Dr. Aimaz Afrough, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 240
Licensed in Texas since 2017, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
TX license R2795 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 240
- Services billed
- 552
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 237 | 65 |
| Established patient office or other outpatient visit, 40-54 minutes | 186 | 78 |
| Established patient office or other outpatient visit, 30-39 minutes | 87 | 81 |
| Hospital discharge day management, more than 30 minutes | 29 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Dallas, TX | 130 |
| Lenalidomide | 119 |
| Revlimid (lenalidomide) | 89 |
| Dexamethasone Other prescribers in Dallas, TX | 67 |
| Ondansetron Hcl Other prescribers in Dallas, TX | 45 |
| Eliquis (apixaban) Other prescribers in Dallas, TX | 29 |
| Pomalyst (pomalidomide) | 28 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Dallas, TX | 27 |
| Lorazepam Other prescribers in Dallas, TX | 24 |
| Prochlorperazine Maleate Other prescribers in Dallas, TX | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 15 payments worth $2,969 in total to this clinician.
| Janssen Biotech, Inc. | $2,161 |
|---|---|
| Genzyme Corporation | $276 |
| Karyopharm Therapeutics Inc. | $221 |
| Janssen Scientific Affairs, LLC | $129 |
| AstraZeneca UK Limited | $96.21 |
| Adaptive Biotechnologies Corporation | $56.27 |
| Tempus Ai, Inc | $29.34 |
| Consulting Fee | $1,897 |
|---|---|
| Food and Beverage | $1,072 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jun 24, 2025 | Consulting Fee TECVAYLI · Oncology | $1,760 |
| Karyopharm Therapeutics Inc. Feb 28, 2025 | Consulting Fee XPOVIO · Oncology | $137 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $910,306 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma
Janssen Research & Development, LLC - A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05137054 - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - M20-258 - Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.